The latest update is out from Iterum Therapeutics ( (ITRM) ).
Iterum Therapeutics has received FDA approval for ORLYNVAH™, an innovative oral treatment for uncomplicated urinary tract infections (uUTIs) in adult women with limited treatment options. This approval marks a significant milestone as ORLYNVAH™ offers a novel solution to combat antibiotic-resistant infections, showcasing superior efficacy in clinical trials. The company aims to leverage this approval to pursue strategic partnerships or commercialization efforts, addressing a critical need in the market for effective uUTI treatments.
For a thorough assessment of ITRM stock, go to TipRanks’ Stock Analysis page.
